Piper Sandler Companies (PIPR)

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the additions of Eric Matthews and Keith Schellhorn as managing directors to its technology investment banking team. “We are excited to welcome Eric and Keith to the Piper Sandler platform. They are proven leaders with deep client relationships and strong track records of execution. Their expertise further strengthens our ability to deliver best-in-class advice and solutions to.

NEW YORK--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the addition of Manuel Navas as managing director and senior research analyst to the financial services equity research group. Navas will be based in the New York office and will cover regional and community banks. “We are thrilled to welcome Manuel to our financial services team. Over his career, Manuel has built strong relationships with the companies he covers and we are confide.

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, is pleased to announce the hiring of Eric Ferdinand as a managing director in the financial services investment banking group. “We are excited to have Eric join our team. Having previously worked with Eric at Sandler O'Neill, we know what a talented banker he is, and we are thrilled to have him back. He has tremendous transaction experience and strong relationships with banks all over the country. We.

Piper Sandler lowered the firm's price target on GitLab to $70 from $85 and keeps an Overweight rating on the shares. While a reiterated full year revenue guide drove consternation in after-hour trading, Q2 showed a markedly improved revenue result vs Q1, along with margins above expectations and large customer momentum, the firm says. GitLab also announced several leadership changes as it plans to continue orienting its GTM engine on expanding new customer velocity and enterprise customer adoption. Piper remains confident in the DevSecOps platform leader as a top idea in its coverage with shares trading at a modest 5.5-times 2026 revenue multiple despite growing over 20% at rule of 40-plus.

Piper Sandler analyst Peter Keith lowered the firm's price target on Dollar Tree to $108 from $112 and keeps a Neutral rating on the shares following Q2 earnings. Q2 was solid with a 6.5% comp that was balanced across both ticket/traffic and consumables/discretionary growth. However, the strong EPS beat wasn't completely flowed through to 2025 guidance, as the second half of the year has some incremental headwinds related to tariffs and general liability claims, the firm notes.

Piper Sandler lowered the firm's price target on Salesforce to $315 from $335 and keeps an Overweight rating on the shares. Investor sentiment on Salesforce remained bearish going into the July-ending print/guide, the firm notes. Despite strong Q2 results and better-than-feared cRPO guide of 9% in cc, Salesforce shares were marked down another -5% after hours with the Q2 beat attributed to FX and licensing tailwinds. Piper says that until it sees a clear path back to double-digit growth, the valuation multiple could continue to compress on bearish sentiment.

Piper Sandler analyst Anna Andreeva assumed coverage of Elf Beauty with an Overweight rating and $150 price target. With the category showing signs of stabilization, Elf's pipeline of innovation robust, comparisons easing the rest of the year, with higher pricing as a tailwind, and contribution from Rhode still ahead, sell side estimates are upwardly biased, the firm says. Piper believes its price target is warranted given that the core business is healthy and potentially accelerating as well as upside from the new growth asset.

Piper Sandler raised the firm's price target on MongoDB to $345 from $275 and keeps an Overweight rating on the shares. The firm cites higher estimates and higher EV/free cash flow target multiple at 28-times based on robust cloud database demand. Strong Q2 results breathe life back into this AI infrastructure beneficiary with Atlas poised to surpass a $2B run-rate next year on 20%-plus growth prospects, Piper says. The firm recommends mid-cap growth investors revisit MongoDB ahead of the NYC user event and analyst day next month.

Piper Sandler raised the firm's price target on Ollie's Bargain Outlet to $150 from $123 and keeps an Overweight rating on the shares. Fundamentals across the discount retailer space have improved as cleaner stores have allowed for trade-down benefits, but despite solid fundamentals, the set-up is "tricky" as the company likely has to raise the full year outlook to support shares at current levels, the analyst tells investors in a research note. 28 Aug

Piper Sandler analyst Peter Keith raised the firm's price target on Dollar Tree to $112 from $93 and keeps a Neutral rating on the shares. Fundamentals across the discount retailer space have improved as cleaner stores have allowed for trade-down benefits, but despite solid fundamentals, the set-up is "tricky" as the company likely has to raise the full year outlook to support shares at current levels, the analyst tells investors in a research note. 03 Sep

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too high. Summit is perceived as having the next Keytruda and as being a takeover candidate, but there is uncertainty around the reproducibility of the China datasets and lack of overall survival benefit seen to date, the analyst tells investors in a research note. As such, Piper prefers to wait for a better entry point.

Piper Sandler raised the firm's price target on Ormat Technologies to $90 from $78 and keeps a Neutral rating on the shares. Shares are up 33% year to date as the improving regulatory environment and demand for AI-related baseload power generation has driven a significant re-rating story, the analyst tells investors in a research note. 12 Dec

As previously reported, Piper Sandler initiated coverage of Janux Therapeutics with an Overweight rating and $42 price target. While noting that investor sentiment has waned over the course of 2025 following the announcement of completion of the JANX007 dose escalation and emergence of competitor clinical data, it continues to think JANX007 is "a differentiated, potentially best-in-class program" in metastatic castration-resistant prostate cancer. The firm views the recent stock pullback offering "an attractive entry point" ahead of clinical updates due later this year, the analyst added. 05 Dec

Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines with an Overweight rating and $75 price target. The firm believes the stock's value will be driven by confidence in daraxonrasib's second-line metastatic pancreatic ductal adenocarcinoma opportunity given the "highly encouraging" data presented to date. Piper sees share upside ahead of the first-line mPDAC data disclosure in the second half of 2025, which it believes could more than double the addressable patient population for daraxonrasib. 04 Dec

Piper Sandler initiated coverage of Day One Biopharmaceuticals with an Overweight rating and $25 price target. Piper thinks the stock move following the first two 2025 earnings reports is overdone and that these early decelerations of Ojemda are artifacts of a unique cancer indication wherein the prescribing physicians are risk-averse and slow to adopt novel therapies, the analyst tells investors in a research note. The firm continues to believe the clinical data will support strong penetration longer term.